[Skip to Navigation]
[Skip to Navigation Landing]
November 1980

Role of Calcitonin in Osteosclerosis of Myeloma?-Reply

Arch Intern Med. 1980;140(11):1554. doi:10.1001/archinte.1980.00330220092040

Unfortunately, the article of Rousseau et al came to our attention after our article was published in the Archives. Their observation of hypercalcitoninemia in osteosclerotic myeloma is interesting and may be important. It may mean that, in their patient, plasma cells were capable of producing and secreting CT. High plasma levels of CT were found in patients with cancer of the breast, cancer of the pancreas, oat cell carcinoma of the lung, and several other malignant neoplasms. In some, but not all of them, skeletal metastases were detected.1 However, the suggestion of Rousseau et al that hypercalcitoninemia may be responsible for osteosclerotic lesions in myeloma is debatable. According to Deftos,2 calcitonin inhibits bone resorption due to an inhibition of osteoclast activity. The evidence for promotion of bone formation is not conclusive and is even controversial. Certainly, patients with myeloma and osteosclerotic lesions may also have separate osteolytic lesions,